1A)  A major scientific gap is the limited availability of controlled clinical studies in dogs, cats, and horses. Many formulations still rely on human or generalized animal data, which overlook key differences in metabolism, digestive physiology, pharmacokinetics, and dose response. These variations affect safety, bioavailability, and efficacy. For example, glucuronidation capacity differs widely across species, meaning ingredients tolerated by humans may be unsafe or ineffective for pets (1).

 1B)  The global pet supplement market is expanding quickly, driven by humanization and premiumization trends that mirror human wellness. Owners increasingly treat pets as family and invest in products promising better health and longevity. Yet a major scientific gap remains: species specific clinical research. Human data can guide hypotheses but cannot substantiate pet claims. Only studies in the target species can determine proper dosing, safety margins, and true benefits. Without this evidence, claims risk being misleading and animals may not receive the intended support.

1C) The humanization of pets can inform or mislead. It increases interest in health and higher quality ingredients but also creates unrealistic expectations when human standards are applied without species‑appropriate data. “Human‑grade” claims highlight this gap; the term only means ingredients are fit for human consumption, but many owners assume superior efficacy for animals (2). Marketing cues, cognitive bias, and limited species‑specific standards widen the perception gap and shape consumer understanding.

1D) Purity is the top priority for pet ingredients because any contaminant risk can trigger recalls and damage trust. Brands favor suppliers meeting AAFCO and NASC standards. Standardization ensures consistent potency, while species‑specific bioavailability data strengthens credibility. Ingredients must also remain stable through extrusion, baking, and retort to maintain effective active levels.

1E) Clean label, sustainability, and transparency are now major purchase drivers, with pet owners seeking natural, traceable, and responsibly sourced ingredients. Although “clean” has no regulatory definition, it reflects concerns about additives, processing, and perceived links to skin or digestive issues. Sustainability expectations are rising, with 58% of consumers preferring sustainable products and claims like recyclable packaging, sustainable proteins, and verified sourcing driving value‑focused purchasing (3).

1F) Evidence for pet supplements typically draws from a combination of preclinical research, species specific trials, veterinary expertise, owner reported outcomes, and, when appropriate, supportive human data. However, expectations are shifting toward more rigorous, animal specific substantiation. Because the feeding behaviors and nutritional needs of dogs, cats, and horses differ significantly, data from humans or rodent models cannot be generalized to companion animals. Robust palatability, digestibility, and functional studies conducted in the target species are increasingly viewed as essential for credible claims and market success.

1G) Consumers struggle to judge whether functional claims are supported by controlled research because pet supplements lack a clear structure and function framework. AAFCO allows only limited ingredient claims, and VOHC review applies only to dental products. Most categories lack standardized verification, making strong substantiation, precise labeling, and avoidance of implied therapeutic claims essential for trust.

1H) Clinical trials in companion animals face major variability in lifestyle, diet, environment, and owner compliance, creating significant noise. Validated veterinary biomarkers remain limited, making rigorous, species‑appropriate methods essential. Although preventive studies need smaller cohorts, progress requires stronger collaboration, with pre‑competitive partnerships improving protocols, sharing costs, and raising overall research quality.

1I) Owner reported outcomes can complement veterinary assessments by capturing clear, noticeable changes, but they are less reliable for subtle or slowly progressing effects. Bias from caregiver placebo, investment, and selective recall is common. These measures are useful only when paired with objective, validated endpoints and study designs that address their limitations.

1L) Ingredients for healthy aging are expanding, especially those supporting joints, mobility, cognition, and vitality. Sustainability is also a growing purchase driver, particularly for premium and younger owners. Interest is rising in upcycled animal proteins, insect proteins, collagen byproducts, and traceable marine oils, including certified sustainable fish oils and algal EPA and DHA, along with antioxidants, fermentation‑derived actives, and postbiotics. Dogs adopt novel proteins faster, while cats advance more slowly due to dietary constraints.

2A) Formulating pet supplements mirrors many human product challenges, but palatability and dosing accuracy are especially critical. Label claims must match the active levels delivered in the daily dose, accounting for processing and storage losses. Early palatability testing, particularly for cats, is essential because selective eating can undermine even strong formulas. Stability and dosing accuracy also drive performance. Standards such as British Retail Consortium Global Standards (BRCGS) require proof that actives remain stable through processing and shelf life, and ingredients that can be reliably measured and certified help build consumer confidence (4).

2B) Delivery format strongly shapes compliance. Chews and soft chews suit dogs because they are easy to give and resemble treats, especially when flavored to mask strong odors. Cats accept chews far less readily, making powders and food toppers more practical. Liquids are uncommon due to palatability and dosing challenges, though oil‑based sprays can help. Fresh or personalized food formats add complexity but create room for innovation and customization.

2C) Interest in simpler, single‑ingredient concepts is rising, especially for export markets, because each active requires full documentation and scientific support during registration. Fewer actives create a smoother regulatory path. However, in Singapore and Thailand, multi‑ingredient formulas remain popular because consumers perceive broader benefits and better value. Single‑ingredient products can still succeed in these markets when backed by strong species‑specific research. Antinol, derived from New Zealand green‑lipped mussel oil, is a leading example dominating the joint category in both countries.

2D) Species differences strongly shape formulation decisions. Cats are highly sensitive to taste and smell, require lower daily doses, and often eat small, frequent meals, which can complicate powder delivery if they do not finish the full portion. Ingredients left in uneaten food may also degrade. Dogs are more flexible, though size and life stage still matter; seniors need joint, cognitive, and anti‑inflammatory support, while puppies and kittens require gentler formulas with precise dosing. Therefore, formulations tailored for each species and life stage ensure safety, palatability, and consistent delivery of active ingredients.

2E) Sustainability and personalized nutrition are shaping pet food, increasing interest in alternative omega‑3 sources such as algae to complement or replace fish‑derived EPA and DHA. These options offer better traceability, supply stability, and lower environmental impact. In Thailand, fish and krill oils remain the most trusted and cost‑effective despite issues like oxidation, odor, heavy metals, and supply volatility. Premium segments are driving interest in sustainable omega‑3s, but AAFCO and FEDIAF minimum EPA and DHA levels often still require fish or krill oil.

4A) Over the next decade, credibility will rely on scientific rigor, transparency, and measurable outcomes. Integrated platforms linking nutrition, supplements, and personalized guidance will expand, and brands will build tiered lines combining daily diets with functional treats and targeted supplements. As healthy ageing gains importance, demand for evidence‑based support will rise. Brands that invest in species‑specific research, clear dose rationale, and sustainability will earn lasting trust.

4B) The biggest barrier to consumer trust is the lack of a unified global framework for structure/function claims. With cross border e-commerce expanding access, pet owners struggle to judge safety and quality, and manufacturers face inconsistent regional standards. A harmonized system aligning AAFCO, FEDIAF, GPFA, and WSAVA principles would clarify expectations and streamline development. Looking ahead, veterinarians and science literate owners will expect stronger evidence, making real world data and transparency central to long term credibility.